Enodia Therapeutics acquired Kezar Life Sciences’ Sec61-based discovery and development assets in a deal that pays $1 million upfront and up to $127 million in future development, regulatory and commercial milestones, plus tiered royalties. Enodia said the transaction adds preclinical datasets and chemotypes that complement its selective Sec61 modulation and targeted protein degradation platform. Enodia CEO Yves Ribeill framed the acquisition as a way to accelerate rational small-molecule design for Sec61 selectivity, citing added proteomics, Cryo-EM and tailored cell-line data from Kezar. Kezar CEO Chris Kirk said his company retains conviction in Sec61 biology even as it divests the program. The deal concentrates early Sec61 assets with a company expressly focused on secretome/secreted and membrane protein targets, a strategy that could unlock targets traditionally considered undruggable by acting at the point of protein synthesis rather than downstream.